ProQR Therapeutics (PRQR) Income from Continuing Operations (2021 - 2025)
Historic Income from Continuing Operations for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to -$13.2 million.
- ProQR Therapeutics' Income from Continuing Operations fell 3781.35% to -$13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$49.2 million, marking a year-over-year decrease of 6988.18%. This contributed to the annual value of -$30.0 million for FY2024, which is 15.84% down from last year.
- Per ProQR Therapeutics' latest filing, its Income from Continuing Operations stood at -$13.2 million for Q3 2025, which was down 3781.35% from -$13.9 million recorded in Q2 2025.
- In the past 5 years, ProQR Therapeutics' Income from Continuing Operations registered a high of -$3.9 million during Q2 2024, and its lowest value of -$20.0 million during Q3 2022.
- Its 5-year average for Income from Continuing Operations is -$12.7 million, with a median of -$12.7 million in 2022.
- As far as peak fluctuations go, ProQR Therapeutics' Income from Continuing Operations soared by 5974.5% in 2023, and later tumbled by 25765.03% in 2025.
- Quarter analysis of 5 years shows ProQR Therapeutics' Income from Continuing Operations stood at -$19.8 million in 2021, then skyrocketed by 35.87% to -$12.7 million in 2022, then surged by 46.95% to -$6.7 million in 2023, then plummeted by 59.73% to -$10.8 million in 2024, then decreased by 22.46% to -$13.2 million in 2025.
- Its Income from Continuing Operations stands at -$13.2 million for Q3 2025, versus -$13.9 million for Q2 2025 and -$11.4 million for Q1 2025.